2025-05-21T08:16:14-05:00 2024-09-30 881478669 CBIZ ADVISORS LLC 1899 L STREET NW 850 WASHINGTON DC 20036 990 2023-10-01 431131436 LUPUS FOUNDATION OF AMERICA INC LUPU 2023491155 2121 K STREET NW 200 WASHINGTON DC 20037 CYNTHIA MEEKINS CHIEF FINANCIAL OFFICER 2023491155 2025-05-20 1 0 AARON M FOX P01365820 2022274000 2025-05-20 2023 2025-03-06 01:10:19Z CYNTHIA MEEKINS 2121 K STREET NW 200 WASHINGTON DC 20037 15488535 0 X WWW.LUPUS.ORG X 1977 DC IMPROVE THE QUALITY OF LIFE FOR PEOPLE WITH LUPUS THROUGH RESEARCH, EDUCATION, SUPPORT AND ADVOCACY. 19 19 64 1025 262750 45661 15780800 13240424 1382047 1925082 44531 256866 41366 6232 17248744 15428604 957355 1228516 0 0 7378867 8139633 51900 119200 2281396 6777829 7616271 15165951 17103620 2082793 -1675016 15514074 13653637 7523086 7222505 7990988 6431132 X LUPUS FOUNDATION OF AMERICA, INC. (THE FOUNDATION) IS DEDICATED TO IMPROVING THE QUALITY OF LIFE FOR ALL PEOPLE AFFECTED BY LUPUS THROUGH PROGRAMS OF RESEARCH, EDUCATION, SUPPORT, AND ADVOCACY. 0 0 5376534 431130 PUBLIC INFORMATION AND EDUCATION:THE LUPUS FOUNDATION OF AMERICA (LFA) CONDUCTS OUTREACH AND OFFERS PROGRAMS AND SERVICES TO SUPPORT OUR ORGANIZATIONAL GOALS OF REDUCING TIME TO A LUPUS DIAGNOSIS, ENSURING PEOPLE WITH LUPUS HAVE AN ARSENAL OF SAFE AND EFFECTIVE TREATMENTS, AND EXPANDING DIRECT SERVICES AND INCREASING ACCESS TO TREATMENT AND CARE. IN 2024, THE LFA CONTINUED TO EXPAND ITS REACH THROUGH ITS WEBSITE, ONLINE EDUCATION PROGRAMS, AWARENESS CAMPAIGNS, SOCIAL MEDIA MARKETING, CELEBRITY ENGAGEMENT AND COMMUNITY PARTNERSHIPS. OUR WEBSITE IS THE LEADING SOURCE FOR LUPUS-RELATED INFORMATION, WITH 10 MILLION VIEWS ANNUALLY. OUR SOCIAL MEDIA CHANNELS HAVE MORE THAN 450,000 COMBINED FOLLOWERS ACROSS THE SIX MOST POPULAR SOCIAL CHANNELS.IN ORDER TO LEVERAGE OUR EXTENSIVE REACH TO IMPROVE THE LIVES OF ALL PEOPLE WITH LUPUS, WE CREATED AND EXECUTED MULTIPLE SOCIAL MEDIA CAMPAIGNS AS PART OF OUR "SPOTLIGHT SERIES." THESE CAMPAIGNS CALL ATTENTION TO THE DISPROPORTIONATE IMPACT OF LUPUS AMONG DIFFERENT POPULATIONS AND AUDIENCES, SHARING IMPORTANT RESOURCES AND EDUCATIONAL INFORMATION ABOUT LUPUS. THROUGHOUT THE YEAR, THE LFA CONTINUED TO RAISE AWARENESS OF LUPUS. OUR BE FIERCE. TAKE CONTROL. AWARENESS CAMPAIGN SAW MORE THAN 41,000 PEOPLE ACCESS THE CAMPAIGN'S EDUCATIONAL RESOURCES ON WHAT LUPUS IS, SYMPTOMS AND DIAGNOSIS. THE CAMPAIGN AIMS TO RAISE AWARENESS OF LUPUS AND REDUCE TIME TO DIAGNOSIS FOR YOUNG BLACK/ AFRICAN AMERICAN AND LATINA/HISPANIC AMERICAN WOMEN, WHO HAVE A HIGHER CHANCE OF DEVELOPING LUPUS IN THEIR LIFETIME.DURING LUPUS AWARENESS MONTH IN MAY THE LFA'S THEME WAS "MAKE LUPUS VISIBLE." EACH WEEK, WE UTILIZED OUR COMMUNICATIONS CHANNELS TO HIGHLIGHT A DIFFERENT ASPECT OF LIFE WITH LUPUS BY FEATURING A LUPUS WARRIOR, SHARING USEFUL RESOURCES, AND PROVIDING AWARENESS FACTS. WE ALSO DEVELOPED AND SHARED A LUPUS AWARENESS MONTH TOOLKIT WITH SHAREABLE LUPUS FACTS, IMAGES, RESOURCES, AND SAMPLE SOCIAL MEDIA COPY. WE ALSO ATTENDED THE NATIONAL MINORITY HEALTH ASSOCIATION LUPUS CALL TO ACTION DAY AT NYU LANGONE. OUR EFFORTS TO RAISE AWARENESS SPANNED SOCIAL MEDIA, EMAIL AND MEDIA PLACEMENTS. 4296251 NETWORK SUPPORT AND SERVICES:THE LUPUS FOUNDATION OF AMERICA'S NATIONAL NETWORK INCLUDES CHAPTERS, REGIONAL OFFICES, AMBASSADORS AND SUPPORT GROUPS ACROSS THE UNITED STATES. NETWORK AFFILIATES CONDUCT EDUCATION PROGRAMS AND SUPPORT RESEARCH, ALONG WITH PROVIDING INFORMATION, SUPPORT AND ADVOCACY TO IMPROVE THE QUALITY OF LIFE FOR THOSE AFFECTED BY LUPUS.THE LFA PROVIDES NETWORK AFFILIATES WITH CAPACITY-BUILDING SERVICES, ORGANIZATIONAL DEVELOPMENT, STRATEGIC SUPPORT, TRAINING AND CONSULTATION. OUR NATIONAL AMBASSADOR PROGRAM CONTINUES TO GROW, WITH THESE COMMITTED AND SPECIALLY TRAINED VOLUNTEERS PLAYING A VITAL ROLE IN SUPPORTING THE FOUNDATION'S MISSION. WE HAVE OVER 176 TRAINED AMBASSADORS WHO PROVIDE COMMUNITY-BASED, PEER-TO-PEER EDUCATION AND SUPPORT. THE LFA ALSO PROVIDES OVERSIGHT AND RESOURCES TO MORE THAN 70 DIFFERENT SUPPORT GROUPS AND 135 TRAINED SUPPORT GROUP FACILITATORS WHO SERVE CONSTITUENTS NATIONWIDE. IN 2024, THE LFA EXPANDED ITS SUPPORT GROUPS TO SERVE MORE INDIVIDUALS WHO ARE AFFECTED BY LUPUS. THESE INCLUDE LUPUS SUPPORT GROUPS FOCUSED ON POPULATIONS WITH A HIGH DISEASE PREVALENCE AND/OR REQUIRE UNIQUE NEEDS IN DISEASE MANAGEMENT, SUCH AS: MEN, YOUTH AGES 21 AND UNDER, BLACK WOMEN, LUPUS WARRIORS AND THEIR LOVED ONES IN THE ASIAN COMMUNITY, BILINGUAL AND SPANISH SUPPORT FOR LUPUS WARRIORS AND LOVED ONES IN THE HISPANIC COMMUNITY, THOSE SERVING IN THE MILITARY AND THEIR FAMILY MEMBERS, NEWLY DIAGNOSED LUPUS WARRIORS, THOSE AT RISK AND IMPACTED BY LUPUS NEPHRITIS (LN), THOSE LIVING WITH THE CHALLENGES OF CENTRAL NERVOUS SYSTEM LUPUS (CNS), CAREGIVERS, GRIEF SUPPORT FOR THOSE WHO HAVE LOST A LOVED ONE TO LUPUS, AND SPIRITUAL SUPPORT. WE ALSO HAVE A WEEKLY OPEN FORUM FOR PEERS TO ASK QUESTIONS. OUR GROUPS ARE OPEN TO EVERYONE AND OFFERED BOTH IN-PERSON AND VIRTUALLY TO ENSURE GREATER ACCESS TO THIS VALUABLE RESOURCE.THE LFA CONTINUES ITS LEADERSHIP ROLE OF THE WORLD LUPUS FEDERATION (WLF), A GLOBAL COALITION OF MORE THAN 200 LUPUS PATIENT ADVOCACY GROUPS FROM OVER 75 COUNTRIES. THE WLF'S MISSION IS TO ADVANCE LUPUS AWARENESS AND ADVOCACY INITIATIVES THAT BRING GREATER ATTENTION AND RESOURCES TO THE FIGHT TO END LUPUS WORLDWIDE. IN 2024, THE WLF CONDUCTED A GLOBAL PATIENT SURVEY FOCUSED ON STEROIDS USE REVEALING THAT 91% OF RESPONDENTS HAVE TAKEN ORAL STEROIDS FOR LUPUS TREATMENT. MORE THAN 7,700 PEOPLE LIVING WITH LUPUS FROM OVER 100 COUNTRIES PARTICIPATED IN THE SURVEY. ADDITIONALLY, THE LFA AND WLF DEVELOPED CO-BRANDED FACT SHEETS ON "UNDERSTANDING LUPUS'' IN SPANISH FOR WLF PATIENT GROUPS IN HONDURAS, NICARAGUA AND PUERTO RICO. THE LFA ALSO ENGAGED WITH VOLUNTEERS AND SUPPORTERS THROUGHOUT THE U.S. WE HELD 29 WALK TO END LUPUS NOW EVENTS ACROSS THE COUNTRY ALLOWING FOR IMPORTANT CONNECTION AND ENGAGEMENT AMONG WALK PARTICIPANTS, SPONSORS AND VOLUNTEERS, AS WELL AS THE OPPORTUNITY TO RAISE AWARENESS AND FUNDS VITAL TO IMPROVING THE QUALITY OF LIFE FOR ALL PEOPLE AFFECTED BY LUPUS. THE VIRTUAL 6 CHALLENGE, 6 DAYS TO COMPLETE 6 MILES, PART OF THE LFA'S TEAM MAKE YOUR MARK ENDURANCE PROGRAM, CONTINUES TO PROVIDE A UNIQUE OPPORTUNITY FOR PEOPLE ACROSS THE COUNTRY TO PARTICIPATE IN THE WAY THAT BEST MEETS THEIR NEEDS AND INTERESTS. IN ADDITION, MORE THAN 188 CONTENT CREATORS JOINED US FOR GAME ON! TO END LUPUS, OUR THREE-DAY LIVE STREAM EVENT WHERE STREAMERS FROM AROUND THE WORLD RAISE AWARENESS OF LUPUS AND FUNDS FOR LUPUS RESEARCH. 2885831 1228516 1068492 RESEARCH:DUE TO RECENT ADVANCES IN THERAPIES, ROUGHLY 97 PERCENT OF LUPUS PATIENTS ARE ABLE TO LIVE AT LEAST 5 YEARS AFTER DIAGNOSIS. RESEARCH FOCUSED ON IMPROVING THE QUALITY OF LIFE FOR PEOPLE LIVING WITH LUPUS AND ADVANCING OUR UNDERSTANDING OF THE DISEASE IS MORE CRITICAL NOW THAN EVER BEFORE. OUR NATIONAL RESEARCH PROGRAM MIRRORS THAT OF THE NATIONAL INSTITUTES OF HEALTH (NIH) WHERE THE ACTION PLANS ARE FOCUSED ON ADDRESSING KEY AREAS RELATED TO LUPUS RESEARCH INCLUDING:- LUPUS AS A SPECTRUM DISEASE.- DEVELOPMENT OF NEW TECHNOLOGIES TO CLOSE THE GAP IN OUR UNDERSTANDING OF DISEASE MECHANISMS.- SUPPORTING THE DEVELOPMENT OF NOVEL TREATMENT PARADIGMS.- WORKING IN TANDEM WITH PARTNERS TO SUPPORT LUPUS RESEARCH AND RESEARCH TRAINING. THE LFA CONTINUES TO LEAD INITIATIVES TO OVERCOME BARRIERS THAT INHIBIT PROGRESS IN DEVELOPING AND APPROVING NEW, EFFECTIVE AND TOLERABLE TREATMENTS FOR PEOPLE WITH LUPUS, INCLUDING:- LEADING THE ADDRESSING LUPUS PILLARS FOR HEALTH ADVANCEMENT (ALPHA) PROJECT, A GLOBAL MULTI-PHASE INITIATIVE TO ADDRESS PATIENT-PROVIDER COMMUNICATION GAPS THROUGH THE CREATION OF AN INNOVATIVE SHARED DECISION-MAKING TOOL. DURING THE REPORTING PERIOD, WE ESTABLISHED A STRONG FOUNDATION BY CONDUCTING A SYSTEMATIC LITERATURE REVIEW OF DECISION AIDS, COMMUNICATION STRATEGIES AND KEY FEATURES THAT ENHANCE PATIENT DECISION MAKING IN THE CLINICAL SETTING AND IMPROVE MEASURABLE HEALTH OUTCOMES. BASED ON THESE FINDINGS, WE HAVE BEGUN THE DEVELOPMENT OF A SHARED DECISION MAKING TOOL THAT INTEGRATES BEST PRACTICES FROM THE LITERATURE AND INSIGHTS FROM KEY PARTNERS SPECIALIZING IN SHARED DECISION-MAKING, LUPUS AND EFFECTIVE COMMUNICATION WITH THE MOST VULNERABLE POPULATIONS. THIS TOOL WILL INCORPORATE THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) SLE GUIDELINES, WITH ALIGNED COMPONENTS FROM THE EULAR GUIDELINES TO ENSURE COMPREHENSIVE, EVIDENCE-BASED SUPPORT FOR PATIENT DECISION-MAKING.- LAUNCHING THE PREDICT AND PREVENT LUPUS RESEARCH GRANT. THE RECIPIENT OF THIS AWARD IS DR. KAREN COSTENBADER, A PROFESSOR AT HARVARD AND RHEUMATOLOGIST AND BRIGHAM AND WOMEN'S HOSPITAL. HER PROJECT ENTITLED, COMMUNITY ACTION FOR RESILIENCE AGAINST LUPUS. THIS WORK USES A LUPUS RISK PREDICTION MODEL BASED ON FAMILY HISTORY AND KNOWN RISK FACTORS TO IDENTIFY WOMEN AT INCREASED RISK FOR LUPUS. THE CARE-LUPUS STUDY WILL RECRUIT FIRST DEGREE RELATIVES OF LUPUS PATIENTS ENROLLED IN THE RESEARCH ACCELERATED FOR YOU (RAY) U.S.-WIDE REGISTRY AND THE BRIGHAM AND WOMEN'S HOSPITAL LARGE LUPUS POPULATION.- SUPPORTING A MULTI-YEAR STUDY OF MESENCHYMAL STROMAL CELLS AS A POTENTIAL TREATMENT FOR LUPUS. THE MEDICAL UNIVERSITY OF SOUTH CAROLINA AND ITS TANGENTIAL NINE CLINICAL SITES ARE NEARING COMPLETION OF ENROLLMENT WITH 80 OF 81 PATIENTS FOR THE PHASE II STUDY ENTITLED, "A PHASE II CONTROLLED TRIAL OF HUMAN ALLOGENEIC UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELLS (MSCS) FOR THE TREATMENT OF REFRACTORY LUPUS." INVESTIGATORS EXPECT TO FINISH THE STUDY IN EARLY 2026 AND HAVE ACQUIRED ADDITIONAL SUPPORT TO CONTINUE WITH PHASE III RESEARCH AND DATA ANALYTICS. - RECRUITING MORE THAN 1,200 NEW PEOPLE WITH LUPUS TO PARTICIPATE IN RESEARCH ACCELERATED BY YOU (RAY), A LUPUS REGISTRY FOR PEOPLE WITH LUPUS AND CAREGIVERS (ON BEHALF OF THE LUPUS PATIENT) TO SHARE INFORMATION ABOUT THEIR LUPUS EXPERIENCE. WE HAVE ALSO INCREASED THE REPRESENTATIVENESS OF THE POPULATION ENROLLED IN THE REGISTRY. THE RAY PLATFORM IS BEING UPGRADED TO EXPAND OUR EFFORTS TO THE GLOBAL LUPUS COMMUNITY. WE HAVE PARTNERED WITH THE MEDICAL UNIVERSITY OF SOUTH CAROLINA AND THE ALLEGHENY HEALTH NETWORK TO DIVERSIFY OUR RECRUITMENT EFFORTS.- FUNDING GRADUATE AND UNDERGRADUATE STUDENT FELLOWSHIPS AND EARLY CAREER DEVELOPMENT GRANTS TO SUPPORT A NEW GENERATION OF LUPUS CLINICIAN-SCIENTISTS. THESE AWARDS ADDRESS A SEVERE LOSS OF CURRENT AND FUTURE LUPUS INVESTIGATORS DUE TO A DECLINE IN FEDERAL TRAINING SUPPORT. PARTNERING WITH LUPUS CANADA FOR A FIFTH YEAR TO MANAGE THEIR CATALYST GRANT, WHICH PROVIDES ONE-YEAR FUNDING TO CANADIAN RESEARCHERS AT ANY STAGE IN THEIR CAREERS. THE LFA ALSO EXPANDED AND LAUNCHED NEW STRATEGIC PARTNERSHIPS WITH ORGANIZATIONS THAT PLAY A CENTRAL ROLE IN ADVANCING LUPUS SCIENCE. PART OF THE LFA'S EFFORTS AND SUPPORT FOR THESE STRATEGIC PARTNERSHIPS INCLUDED:- FUNDING THE IMPACT (IMPROVE PREGNANCY IN APS WITH CERTOLIZUMAB THERAPY) PHASE II TRIAL OF A BIOLOGIC THERAPY TO PREVENT ADVERSE OUTCOMES IN HIGH-RISK PREGNANCIES AMONG PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, WITH OR WITHOUT SYSTEMIC LUPUS ERYTHEMATOSUS. THIS STUDY WILL BE COMPLETED IN MARCH 2025.- CONTINUING OUR SUPPORT OF THE SYSTEMIC LUPUS ERYTHEMATOSUS COLLABORATING CLINICS (SLICC), A GLOBAL BODY OF LUPUS EXPERTS, TO UPDATE THE SLICC DAMAGE INDEX, THE ONLY FOOD AND DRUG ADMINISTRATION (FDA)-ACCEPTED OUTCOME MEASURE FOR LUPUS CLINICAL TRIALS. THE SLICC TEAM HAS DEVELOPED A NEW DISEASE ACTIVITY INDEX THAT IS MORE COMPREHENSIVE AND ACCOUNTS FOR DISEASE RESOLUTION THAT MAY BE POSSIBLE WITH THE ADVENT OF NEW CAR-T CELL THERAPIES THAT HAVE RECENTLY ENTERED THE LUPUS RESEARCH ECOSYSTEM.- PARTICIPATING IN LUPUS ABC, A PUBLIC-PRIVATE PARTNERSHIP LED BY THE LUPUS RESEARCH ALLIANCE IN COLLABORATION WITH THE FOOD AND DRUG ADMINISTRATION TO IMPROVE LUPUS CLINICAL TRIAL OUTCOME MEASURES.- PARTNERING IN THE TREATMENT RESPONSE MEASURE FOR SLE (TRM-SLE) PROJECT WHERE WE WORK TO PRIORITIZE THE PATIENT VOICE ON THE STEERING AND ADVISORY COMMITTEES FOR THE PROJECT.THROUGH OUR DIRECT FUNDING SUPPORT AND VARIOUS FOUNDATION INITIATIVES, WE INVESTED OVER $1 MILLION TO FUND PEER-REVIEWED RESEARCH GRANTS, AWARDS TO INVESTIGATORS, RESEARCH PARTNERSHIPS AND COLLABORATIVE PROJECTS. AS PART OF OUR RESEARCH FUNDING EFFORTS, THE FOUNDATION WORKED WITH CONGRESS AND FEDERAL AGENCIES TO SECURE $160 MILLION IN PUBLIC FUNDING FOR LUPUS RESEARCH AND EDUCATION PROGRAMS IN FY24 AND ARE WORKING TO SECURE AN ADDITIONAL $173 MILLION IN FY25, INCLUDING FUNDING FROM THE NATIONAL INSTITUTES OF HEALTH, THE CENTERS FOR DISEASE CONTROL AND PREVENTION, THE DEPARTMENT OF DEFENSE AND THE OFFICE OF MINORITY HEALTH.THE LUPUS FOUNDATION OF AMERICA CONTINUES TO ACCELERATE CLINICAL TRIALS BY USING MULTIDIMENSIONAL APPROACHES TO IMPACT IMPORTANT FACTORS THAT SHAPE THE DRUG DEVELOPMENT PIPELINE. THE LFA PROFESSIONAL ONLINE INSTRUMENT TRAINING (LFA POINT) IS THE GOLD-STANDARD ONLINE TRAINING AND TESTING SITE FOR CLINICAL TRIAL OUTCOME MEASURES USED IN THE ASSESSMENT OF PEOPLE WITH LUPUS IN CLINICAL TRIALS. THIS YEAR NEARLY 7,500 CERTIFICATES WERE AWARDED TO HEALTH CARE PROFESSIONALS COMPLETING THE TRAINING. 350368 PATIENT EDUCATION AND SUPPORT:THE LUPUS FOUNDATION OF AMERICA REMAINS A LEADER IN LUPUS EDUCATION, AND ONCE AGAIN PROVIDED EDUCATION, SUPPORT, AND OTHER ASSISTANCE TO INDIVIDUALS WITH LUPUS, THEIR FAMILIES AND CAREGIVERS.OUR EDUCATIONAL WEBSITE, THE NATIONAL RESOURCE CENTER ON LUPUS (NRCL), REMAINS THE MOST COMPREHENSIVE LUPUS EDUCATION SITE AVAILABLE. THE NRCL SERVES AS THE FIRST STOP FOR PEOPLE SEARCHING FOR BASIC INFORMATION ON LUPUS AND LOCAL RESOURCES. WE CONTINUED TO CREATE HEALTH EDUCATION RESOURCES IN A VARIETY OF FORMATS AND LANGUAGES COVERING TOPICS IMPORTANT TO PEOPLE WITH LUPUS. WE PUBLISHED MORE THAN 20 NEW HEALTH EDUCATION RESOURCES ON THE NRCL IN ENGLISH AND SPANISH IN THE PAST YEAR. THE NRCL HAD MORE THAN 6.5 MILLION PAGE VIEWS IN FISCAL YEAR 2024.WE PRODUCED THREE NEW EPISODES OF OUR PATIENT EDUCATION PODCAST, THE EXPERT SERIES, FEATURING LUPUS EXPERTS OFFERING INFORMATION AND INSIGHTS INTO ESSENTIAL TOPICS. THE PODCASTS ARE AVAILABLE THROUGH LUPUS.ORG, YOUTUBE, ITUNES, AND SPOTIFY. TOPICS DURING FISCAL YEAR 2024 INCLUDED STRESS AND STRESS MANAGEMENT, LUPUS AND CANCER, AND LUPUS NEPHRITIS. THESE THREE EPISODES HAD MORE THAN 7,000 PLAYS ACROSS ALL PLATFORMS. IN TOTAL, THERE WERE MORE THAN 24,000 PLAYS OF ALL EPISODES ACROSS ALL PLATFORMS IN FY2024. THE LFA HAS EXPANDED RESEARCH EDUCATION FOR PATIENTS. THIS PAST YEAR, WE LAUNCHED OUR RESEARCH WEBINAR SERIES WITH THE HIGHLY SUCCESSFUL WEBINAR TITLED UNLOCKING CAR T: A SPECIAL EDITION PATIENT EDUCATION WEBINAR. ESTEEMED PANELISTS ALONGSIDE TWO PEOPLE LIVING WITH LUPUS SHARED THEIR EXPERIENCES WITH CAR T CELL THERAPY. THE MEETING ATTRACTED OVER 1,400 REGISTRANTS. OF THOSE, 609 ATTENDED LIVE, WITH 458 UNIQUE LIVE VIEWS. EDUCATION ABOUT TREATMENTS AND UNIQUE THERAPIES IN THE DRUG DEVELOPMENT PIPELINE WILL CONTINUE AS PART OF OUR CORE PROGRAMMING.OUR 12-WEEK LUPUS SELF-MANAGEMENT EMAIL SERIES, TAKE CHARGE, GAINED 1,115 SUBSCRIBERS IN 2024. SINCE ITS LAUNCH IN SEPTEMBER 2023, TOME CONTROL, A CULTURALLY AND LINGUISTICALLY APPROPRIATE SPANISH VERSION OF TAKE CHARGE HAS REACHED 258 SUBSCRIBERS. IN TOTAL, THE PROGRAMS HAVE REACHED ALMOST 17,000 SUBSCRIBERS.LUPUS AND YOU: ANSWERS, ADVOCACY, ACTION (LUPUS & YOU) CONTINUES TO BE OFFERED VIRTUALLY. IN 2024, OUR NATIONAL LUPUS & YOU SERIES REACHED MORE THAN 5,000 PEOPLE, PROVIDING PEOPLE WITH OPPORTUNITIES TO LEARN FROM LEADING EXPERTS, CHAT WITH OUR HEALTH EDUCATORS, AND GET THEIR QUESTIONS ANSWERED NO MATTER WHERE THEY LIVE. WE BEGAN A POST-EVENT BLOG TO CONTINUE TO ANSWER QUESTIONS AND REFER INDIVIDUALS TO OUR RESOURCES. WE ALSO OFFERED OUR FIRST ALL-PATIENT DISCUSSION FOCUSED ON DAILY LIFE WITH LUPUS. OUR ONLINE LUPUS SELF-MANAGEMENT PROGRAM CALLED STRATEGIES TO EMBRACE LIVING WITH LUPUS FEARLESSLY (SELF) ALSO CONTINUED TO GROW. SELF IS A FREE, ONLINE, EVIDENCE-BASED, SELF-MANAGEMENT PROGRAM DESIGNED TO HELP PEOPLE WITH LUPUS BUILD AND ENHANCE SKILLS IN FOUR PILLARS OF LUPUS SELF-MANAGEMENT: MANAGING SYMPTOMS, MANAGING STRESS, MANAGING MEDICATIONS AND WORKING WITH THEIR HEALTHCARE TEAM. IN 2024, SELF GAINED 2,313 ENROLLEES.IN 2024, WE EXTENDED OUR COMMUNITY-LEVEL ENGAGEMENT TO INCLUDE 14 LIBRARIES BY ESTABLISHING HEALTH CORNER DISPLAYS. MATERIALS, SUCH AS A BRANDED VERTICAL BANNER, EDUCATIONAL TABLETOP DISPLAY, AND HEALTH EDUCATION FACTSHEETS, WERE SUCCESSFULLY SHIPPED TO THE LIBRARIES.IN ADDITION, OUR TEAM OF HEALTH EDUCATION SPECIALISTS RESPONDED TO 2,546 INQUIRIES (OF WHICH 355 WERE IN SPANISH) RECEIVED VIA TELEPHONE, EMAIL, AND HANDWRITTEN LETTERS AND GUIDED PEOPLE TO THE APPROPRIATE INFORMATION TO MANAGE THEIR LUPUS. THE HEALTH EDUCATION SPECIALIST'S LUPUS INFORMATION PACKET, A DIGITAL DOCUMENT AVAILABLE IN ENGLISH AND SPANISH, WAS DOWNLOADED 4,029 TIMES IN ENGLISH AND 527 TIMES IN SPANISH OVER THE COURSE OF THE YEAR. 215092 18012 PROFESSIONAL RELATIONS AND EDUCATION:OUR PROFESSIONAL EDUCATION PROGRAMS ARE DESIGNED TO DEVELOP AND INCREASE KNOWLEDGE, SKILLS AND PROFESSIONAL PERFORMANCE OF ALL HEALTHCARE PROVIDERS WHO TREAT PEOPLE WITH LUPUS. WITHIN THESE PROGRAMS, WE WORK TO TRANSLATE RESEARCH FINDINGS INTO PUBLIC HEALTH RECOMMENDATIONS FOR PHYSICIANS, OTHER HEALTHCARE PROFESSIONALS, AND THEIR RESPECTIVE ORGANIZATIONS. IN 2024, WE CONTINUED TO FOCUS ON EXPANDING PARTNERSHIPS WITH ORGANIZATIONS THAT SERVE MEDICAL AND OTHER HEALTHCARE PROFESSIONALS. THE LFA OFFICIALLY LAUNCHED THE COMMUNITY HEALTH WORKER (CHW) RESOURCE HUB IN FEBRUARY 2024 IN PARTNERSHIP WITH CHWS ACROSS THE COUNTRY. THE CHW HUB FEATURES ON-DEMAND LEARNING MODULES TO INCREASE CHW'S KNOWLEDGE ABOUT LUPUS INCLUDING THE SIGNS AND SYMPTOMS, DIAGNOSIS, TREATMENTS, MANAGEMENT, RESOURCES, AND SUPPORT AVAILABLE TO THOSE LIVING WITH LUPUS. THE DEVELOPMENT OF THE HUB ALLOWED THE LFA TO EXPAND ITS CAPACITY BUILDING EFFORTS TO INCLUDE IN-PERSON, VIRTUAL, AND ON-DEMAND. IN 2024, A TOTAL OF 212 CHWS WERE EDUCATED THROUGH ALL MODES OF TRAINING. OUR CONTINUED PARTNERSHIP, EDUCATION, AND OUTREACH EFFORTS IN 2024 ALSO INCLUDED OUR IN-KIND COLLABORATION WITH PATIENTPOINT, A LEADING DIGITAL HEALTH COMPANY THAT CONNECTS PATIENTS, HEALTHCARE PROVIDERS, AND LIFE SCIENCES COMPANIES WITH ACCURATE HEALTH INFORMATION IN THE CLINICAL SETTING. THIS PARTNERSHIP HAS ENABLED US TO PLACE LUPUS AWARENESS, EDUCATION, AND RESOURCE MESSAGING ON DIGITAL SCREENS IN PHYSICIAN OFFICES, SPECIFICALLY WAITING ROOMS, EXAM ROOMS, AND DOCTOR BACK ROOMS. THROUGH THIS DONATED ADVERTISING (VALUED AT $1,113,171), WE WERE ABLE TO REACH NEARLY 31,000 RHEUMATOLOGY AND PRIMARY CARE HEALTH CARE PROFESSIONALS. PUBLISHED IN JUNE 2024, THE LUPUS SCIENCE & MEDICINE (LS&M) IMPACT FACTOR HAS BEEN UPDATED TO 3.7 WITH A CITESCORE OF 5.3. THE IMPACT FACTOR RANKING IS 14/57 UP FROM 17/57 IN 2023. THE JOURNAL CONTINUES TO SEE AN AVERAGE OF 27 SUBMISSIONS EACH MONTH WITH A 33% ACCEPTANCE RATE.THE LUPUS SCIENCE AND MEDICINE PODCAST HAS BEEN A VALUABLE PLATFORM FOR SHARING INSIGHTS AND FOSTERING DIALOGUE ON CRITICAL TOPICS RELATED TO LUPUS RESEARCH AND TREATMENT. THE PODCAST IS AN INVALUABLE RESOURCE FOR CLINICIANS, RESEARCHERS, AND PATIENTS ALIKE, MAKING SIGNIFICANT CONTRIBUTIONS TO THE FIELD OF LUPUS RESEARCH AND IS NOW PUBLISHED ON PODBEAN, A PODCAST HOSTING PLATFORM THAT PROVIDES TOOLS FOR PODCASTERS TO PUBLISH, MANAGE, PROMOTE, AND MONETIZE PODCASTS. WE PUBLISHED 12 NEW PODCASTS COVERING TOPICS FROM THE USE OF KRILL OIL IN TREATING SLE TO TRIPLE THERAPY FOR EFFECTIVE TREATMENT OF LUPUS NEPHRITIS. 565460 18012 13124076 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 70 0 1 64 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 X 19 19 0 0 0 0 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AK AL AR CA CO CT DC FL GA HI IL KS KY LA MA MD ME MI MN MS NC ND NH NJ NM NV NY OH OK OR PA RI SC TN UT VA WA WI WV X X CYNTHIA MEEKINS 2023491155 2121 K STREET NW 200 WASHINGTON DC 20037 JOSEPH A ARNOLD ESQ VICE CHAIR, THEN CHAIR 5.00 1.50 X X 0 0 0 ANDREW BROPHY CHAIR, THEN IMMEDIATE PAST CHAIR 5.00 1.50 X X 0 0 0 BARBARA POLK SECRETARY, THEN VICE CHAIR 5.00 1.50 X X 0 0 0 CHRISTINE SMITH TREASURER 1.00 1.50 X X 0 0 0 PHONG NGUYEN DIRECTOR, THEN SECRETARY 5.00 X X 0 0 0 BRIAN ANTONSEN DIRECTOR AS OF 11/2023 1.00 X 0 0 0 JUDY BARLIN DIRECTOR 1.00 X 0 0 0 LYNN BLANDFORD DIRECTOR 1.00 X 0 0 0 SHANNON BOXX DIRECTOR AS OF 9/2024 1.00 X 0 0 0 LINDSAY CAFRITZ DIRECTOR 1.00 X 0 0 0 KEVIN CHEUNG DIRECTOR AS OF 9/2024 1.00 X 0 0 0 KAREN COSTENBADER MD MPH DIRECTOR 1.00 X 0 0 0 CONRAD GEHRMAN DIRECTOR 1.00 X 0 0 0 THERESA JUDAY DIRECTOR AS OF 11/2023 1.00 X 0 0 0 SREEDHAR MANDAYAM MD MPH DIRECTOR AS OF 6/2024 1.00 X 0 0 0 SUSAN MANZI DIRECTOR 1.00 X 0 0 0 TIM NOLAN DIRECTOR 1.00 X 0 0 0 AMY ONDR DIRECTOR UNTIL 5/2024 1.00 X 0 0 0 CHERI PERRON DIRECTOR 1.00 X 0 0 0 ELIZABETH ROTH DIRECTOR AS OF 6/2024 1.00 X 0 0 0 LOUISE VETTER PRESIDENT CHIEF EXECUTIVE OFFICER AS OF 7/2024 37.50 1.50 X 0 0 0 MARY T CRIMMINGS INTERIM CEO; VP, MARKETING & COMMUNICATIONS 37.50 1.50 X 294832 0 36718 JEANINE SMITH VP, NETWORK DEVELOPMENT 37.50 1.50 X 237267 0 32365 JULIE TUNE CHIEF FINANCIAL OFFICER UNTIL 8/2024 37.50 1.50 X 191822 0 22586 PATRICK WILDMAN VP, ADVOCACY & GOVERNMENT 37.50 1.50 X 215299 0 29743 JOY BUIE VP, RESEARCH 37.50 1.50 X 158479 0 18725 MICHAEL DONNELLY VICE PRESIDENT, COMMUNICATIONS 37.50 1.50 X 200562 0 28194 SUSAN J GLOOR REGIONAL DIRECTOR, NE 37.50 1.50 X 175303 0 25432 MATT DEGOOYER SENIOR REGIONAL DIRECTOR 37.50 1.50 X 156553 0 29236 DESIREE WIENAND DIRECTOR, CORPORATE ENGAGE 37.50 1.50 X 155742 0 25772 AMY YALDEN SENIOR REGIONAL DIRECTOR 37.50 1.50 X 175627 0 19552 1961486 0 268323 26 0 1 0 DAVINCI DIRECT 36 LORING BLVD 339 PLYMOUTH MA 02360 CONSULTING 731302 THE HERALD GROUP LLC 1800 M ST NW 450 WASHINGTON DC 20036 CONSULTING 571000 PRO-CHANGE BEHAVIOR SYSTEM INC 91 POINT JUDITH RD STE 26 UNIT 3 NARRAGANSETT RI 02882 CONSULTING 306452 INTERACTIVE STRATEGIES INC 1133 CONNECTICUT AVE NW STE 600 WASHINGTON DC 20036 WEBSITE/ONLINE RELATED SERVICES 289599 JW MARRIOT HOTEL WASHINGTON DC 1331 PENNSYLVANIA AVE NW WASHINGTON DC 20004 EVENT HOSTING 260218 15 90754 600000 2196321 10353349 85531 13240424 PROG. EVENTS/OTHER 900099 1524574 1524574 PUBLICATIONS 900099 265124 2374 262750 MEMBERSHIP DUES 900099 135384 135384 1925082 257902 257902 6232 6232 58895 59931 -1036 -1036 -1036 15428604 1662332 262750 263098 X 1220516 1220516 8000 8000 1434875 1176711 242761 15403 5419275 4214440 319175 885660 229331 174777 13306 41248 445594 352217 25892 67485 610558 479922 48748 81888 29843 11620 11800 6423 88740 5850 82890 119200 119200 2483233 1972457 458855 51921 711947 711943 4 313974 243463 38940 31571 730337 351962 48929 329446 655142 536176 45751 73215 371258 307980 20790 42488 1191845 887448 84690 219707 404 404 129763 104524 9706 15533 65675 52698 4991 7986 POSTAGE & MAILHOUSE 578369 145609 179135 253625 PRINTING & PUBLICATIONS 215741 165763 11789 38189 BAD DEBT EXPENSE 50000 50000 17103620 13124076 1698148 2281396 X 2070425 1264082 630432 175911 5991670 2162870 3164723 5741843 2073949 1647037 97460 166266 263197 360663 2046815 1550045 568188 496770 315480 377869 3039407 2700319 15514074 13653637 1576336 1662755 1573956 1720656 346000 358628 4026794 3480466 7523086 7222505 X 5372934 3229878 2618054 3201254 7990988 6431132 15514074 13653637 X -1675016 64513 50647 X 0 1 X 1 0 X 10961768 12393471 15979553 15780800 13240424 68356016 10961768 12393471 15979553 15780800 13240424 68356016 5190495 63165521 48732 36120 71866 85897 264134 506749 215000 45671 260671 69123436 7743583 0.91380 0.92290 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 31839 31839 16952583 16984422 999221 249805 0 0 883533 962876 900922 999221 3746552 5619828 69211 53293 45401 31839 199744 220883 240719 225231 249805 936638 1404957 422780 62388 485168 399875 22905 422780 458100 -56419 1806 399875 404842 56936 3678 458100 379279 30200 4637 404842 1.00000 1 0 1061513 666848 394665 428522 375383 53139 556780 507814 48966 496770 DUE FROM LAC 214981 RIGHT OF USE ASSETS 2485338 2700319 RIGHT OF USE LEASE LIABILITIES 3480466 3480466 X 16642068 64513 1148951 1213464 15428604 0 15428604 18201924 1148951 1148951 17052973 50647 50647 17103620 PART V, LINE 4: THE EARNINGS ON THE DONOR-RESTRICTED ENDOWMENT ARE FOR GENERAL OPERATIONS AND RESEARCH. THE FOUNDATION'S BOARD APPROVES THE SPENDING OF THE EARNINGS ON THE ENDOWMENT FUND ON AN ANNUAL BASIS WHEN IT APPROVES THE ANNUAL BUDGET. PART X, LINE 2: THE FOUNDATION PERFORMED AN EVALUATION OF UNCERTAINTY IN TAXES FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. PART XII, LINE 4B - OTHER ADJUSTMENTS: REFUND OF GRANTS 50,647. 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTMAKING 8000 0 0 0 0 0 0 8000 0 8000 0 0 0 0 0 0 0 PART I, LINE 2: ALL GRANT RECIPIENTS ARE REQUIRED TO SIGN THE FOUNDATION'S GRANT AWARD AGREEMENT AND MEET THE FOLLOWING CONDITIONS: - MEET ALL APPLICABLE AND RELEVANT GUIDELINES REGARDING THE USE OF ANIMAL AND HUMAN SUBJECTS. - MEET ALL INSTITUTIONAL POLICIES AND LOCAL, STATE, AND FEDERAL REGULATIONS GOVERNING THE CONDUCT OF RESEARCH. - SUBMIT INTERNAL REVIEW BOARD AND INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IF APPLICABLE) APPROVAL FROM THE GRANT RECIPIENT'S INSTITUTION. - COMPLETE AND SUBMIT THE "PROPOSED BUDGET". - ADHERE TO THE FOUNDATION'S POLICY ON INVENTIONS AND DISCOVERIES. - NOTIFY THE FOUNDATION OF ANY PUBLICATION OR PROFESSIONAL PRESENTATION BASED ON FOUNDATION-FUNDED RESEARCH PROJECT AND PROVIDE THE FOUNDATION WITH ELECTRONIC COPIES OF ANY PUBLICATION OR PROFESSIONAL PRESENTATION MADE POSSIBLE, FACILITATED, EXPEDITED, OR SUPPORTED IN ANY WAY BY THE AWARD, EVEN IF DEVELOPED, INITIATED, OR FINALIZED AFTER THE AWARD PERIOD HAS EXPIRED, WITHIN 30 DAYS OF FINAL PRODUCTION. - ACKNOWLEDGE THE FOUNDATION IN ANY AND ALL PUBLICATIONS OR PRESENTATIONS BASED, PARTIALLY OR WHOLLY, ON OR DEVELOPED UNDER THE AWARD MUST, UNLESS OTHERWISE REQUESTED BY THE FOUNDATION, WITH THE FOLLOWING STATEMENT: "THIS RESEARCH WAS SUPPORTED BY THE LUPUS FOUNDATION OF AMERICA, INC." - ALL FUNDS ARE USED EXCLUSIVELY TOWARD EXPENDITURES FOR THE SAID RESEARCH, AND NO AMOUNT OF THE RESEARCH GRANT FUNDS CAN BE USED TO FINANCE INDIRECT COSTS. - KEEP COMPLETE AND ACCURATE RECORDS ON THE RECEIPT AND DISBURSEMENT OF ALL AWARD FUNDS, AND MAY NOT CO-MINGLE ANY FUNDS FROM OTHER SOURCES. MUST RETAIN ALL SUCH RECORDS FOR A PERIOD OF AT LEAST TWO YEARS AFTER THE EXPIRATION DATE OF THE AGREEMENT AND THE FOUNDATION HAS THE RIGHT TO REVIEW SUCH RECORDS UPON REQUEST. IN ADDITION, ALL GRANT RECIPIENTS ARE REQUIRED TO SUBMIT INTERIM AND FINAL REPORTS WITH A GRANT INSTALLMENT PAYMENT TIED TO REPORT SUBMISSION. THE FOUNDATION'S EDUCATION & RESEARCH TEAM REVIEWS THE INTERIM AND FINAL REPORTS TO CONFIRM THAT THE INVESTIGATOR ACHIEVED THE ORIGINAL STUDY OBJECTIVE. - AGREE THAT EITHER PARTY MAY TERMINATE THE AGREEMENT FOR CONVENIENCE UPON THIRTY (30) DAYS PRIOR WRITTEN NOTICE TO THE OTHER PARTY. THE FOUNDATION RESERVES THE RIGHT TO TERMINATE THE AGREEMENT EFFECTIVE IMMEDIATELY, UPON WRITTEN NOTICE, IF THE GRANT RECIPIENT (I) IS UNABLE TO COMPLETE THE STUDY; (II) MATERIALLY ALTER THE STUDY; (III) USES THE AWARD GRANT FOR PROHIBITED EXPENSES OR; (IV) BREACHES OF THE AGREEMENT AND FAILS TO CURE SUCH BREACH WITHIN TEN (10) DAYS FOLLOWING RECIPIENT'S OR INSTITUTION'S RECEIPT OF WRITTEN NOTICE THEREOF. - ACKNOWLEDGE THAT NEITHER THE FOUNDATION, THE INSTITUTION, NOR INVESTIGATOR SHALL BE LIABLE FOR ANY FAILURE TO PERFORM ANY OBLIGATIONS UNDER THE AGREEMENT IF SUCH FAILURE RESULTS FROM CAUSES BEYOND ITS REASONABLE CONTROL. - ACKNOWLEDGE THAT THE AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE DISTRICT OF COLUMBIA, WITHOUT REGARD TO ITS CONFLICT OF LAW RULES. - ACKNOWLEDGE THAT THE AGREEMENT MAY NOT BE ASSIGNED OR TRANSFERRED WITHOUT THE FOUNDATION'S PRIOR WRITTEN CONSENT. PART I, LINE 3: THE FOUNDATION REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS (ACCRUAL BASIS). X X X 1 DAVINCI DIRECT INC 3 VILLAGE GREEN N SUITE 311 PLYMOUTH MA 02360 DIRECT MAIL 0 888676 769476 119200 888676 769476 119200 AL AK AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI 1 THE BRIGHAM WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 400000 0 RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 501(C)(3) 280000 0 RESEARCH HOSPITAL FOR SPECIAL SURGERY 535 EAST 70TH STREET NEW YORK NY 10021 131624135 501(C)(3) 150000 0 RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 1 SOUTH PARK CIRCLE BUILDING 1 SUITE 402 CHARLESTON SC 29407 576000722 501(C)(3) 140000 0 RESEARCH NEW YORK UNIVERSITY 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 140000 0 RESEARCH BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 45000 0 RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST 5TH FLOOR FRANKLIN BLDG PHILADELPHIA PA 19104 231352685 501(C)(3) 45000 0 RESEARCH 7 0 PART I, LINE 2: ALL GRANT RECIPIENTS ARE REQUIRED TO SIGN THE FOUNDATION'S GRANT AWARD AGREEMENT AND MEET THE FOLLOWING CONDITIONS: - MEET ALL APPLICABLE AND RELEVANT GUIDELINES REGARDING THE USE OF ANIMAL AND HUMAN SUBJECTS. - MEET ALL INSTITUTIONAL POLICIES AND LOCAL, STATE, AND FEDERAL REGULATIONS GOVERNING THE CONDUCT OF RESEARCH. - SUBMIT INTERNAL REVIEW BOARD AND INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IF APPLICABLE) APPROVAL FROM THE GRANT RECIPIENT'S INSTITUTION. - COMPLETE AND SUBMIT THE "PROPOSED BUDGET". - ADHERE TO THE FOUNDATION'S POLICY ON INVENTIONS AND DISCOVERIES. - NOTIFY THE FOUNDATION OF ANY PUBLICATION OR PROFESSIONAL PRESENTATION BASED ON FOUNDATION-FUNDED RESEARCH PROJECT AND PROVIDE THE FOUNDATION WITH ELECTRONIC COPIES OF ANY PUBLICATION OR PROFESSIONAL PRESENTATION MADE POSSIBLE, FACILITATED, EXPEDITED, OR SUPPORTED IN ANY WAY BY THE AWARD, EVEN IF DEVELOPED, INITIATED, OR FINALIZED AFTER THE AWARD PERIOD HAS EXPIRED, WITHIN 30 DAYS OF FINAL PRODUCTION. - ACKNOWLEDGE THE FOUNDATION IN ANY AND ALL PUBLICATIONS OR PRESENTATIONS BASED, PARTIALLY OR WHOLLY, ON OR DEVELOPED UNDER THE AWARD MUST, UNLESS OTHERWISE REQUESTED BY THE FOUNDATION, WITH THE FOLLOWING STATEMENT: "THIS RESEARCH WAS SUPPORTED BY THE LUPUS FOUNDATION OF AMERICA, INC." - ALL FUNDS ARE USED EXCLUSIVELY TOWARD EXPENDITURES FOR THE SAID RESEARCH, AND NO AMOUNT OF THE RESEARCH GRANT FUNDS CAN BE USED TO FINANCE INDIRECT COSTS. - KEEP COMPLETE AND ACCURATE RECORDS ON THE RECEIPT AND DISBURSEMENT OF ALL AWARD FUNDS, AND MAY NOT CO-MINGLE ANY FUNDS FROM OTHER SOURCES. MUST RETAIN ALL SUCH RECORDS FOR A PERIOD OF AT LEAST TWO YEARS AFTER THE EXPIRATION DATE OF THE AGREEMENT AND THE FOUNDATION HAS THE RIGHT TO REVIEW SUCH RECORDS UPON REQUEST. IN ADDITION, ALL GRANT RECIPIENTS ARE REQUIRED TO SUBMIT INTERIM AND FINAL REPORTS WITH A GRANT INSTALLMENT PAYMENT TIED TO REPORT SUBMISSION. THE FOUNDATION'S EDUCATION & RESEARCH TEAM REVIEWS THE INTERIM AND FINAL REPORTS TO CONFIRM THAT THE INVESTIGATOR ACHIEVED THE ORIGINAL STUDY OBJECTIVE. - AGREE THAT EITHER PARTY MAY TERMINATE THE AGREEMENT FOR CONVENIENCE UPON THIRTY (30) DAYS PRIOR WRITTEN NOTICE TO THE OTHER PARTY. THE FOUNDATION RESERVES THE RIGHT TO TERMINATE THE AGREEMENT EFFECTIVE IMMEDIATELY, UPON WRITTEN NOTICE, IF THE GRANT RECIPIENT (I) IS UNABLE TO COMPLETE THE STUDY; (II) MATERIALLY ALTER THE STUDY; (III) USES THE AWARD GRANT FOR PROHIBITED EXPENSES OR; (IV) BREACHES OF THE AGREEMENT AND FAILS TO CURE SUCH BREACH WITHIN TEN (10) DAYS FOLLOWING RECIPIENT'S OR INSTITUTION'S RECEIPT OF WRITTEN NOTICE THEREOF. - ACKNOWLEDGE THAT NEITHER THE FOUNDATION, THE INSTITUTION, NOR INVESTIGATOR SHALL BE LIABLE FOR ANY FAILURE TO PERFORM ANY OBLIGATIONS UNDER THE AGREEMENT IF SUCH FAILURE RESULTS FROM CAUSES BEYOND ITS REASONABLE CONTROL. - ACKNOWLEDGE THAT THE AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE DISTRICT OF COLUMBIA, WITHOUT REGARD TO ITS CONFLICT OF LAW RULES. - ACKNOWLEDGE THAT THE AGREEMENT MAY NOT BE ASSIGNED OR TRANSFERRED WITHOUT THE FOUNDATION'S PRIOR WRITTEN CONSENT. X X X X 0 0 0 0 0 0 0 1 0 MARY T CRIMMINGS INTERIM CEO; VP, MARKETING & COMMUNICATIONS 294832 0 0 0 0 0 26512 0 10206 0 331550 0 0 0 JEANINE SMITH VP, NETWORK DEVELOPMENT 217267 0 20000 0 0 0 15374 0 16991 0 269632 0 0 0 PATRICK WILDMAN VP, ADVOCACY & GOVERNMENT 207299 0 8000 0 0 0 14761 0 14982 0 245042 0 0 0 MICHAEL DONNELLY VICE PRESIDENT, COMMUNICATIONS 192562 0 8000 0 0 0 13945 0 14249 0 228756 0 0 0 JULIE TUNE CHIEF FINANCIAL OFFICER UNTIL 8/2024 191822 0 0 0 0 0 9571 0 13015 0 214408 0 0 0 SUSAN J GLOOR REGIONAL DIRECTOR, NE 171303 0 4000 0 0 0 12368 0 13064 0 200735 0 0 0 AMY YALDEN SENIOR REGIONAL DIRECTOR 171627 0 4000 0 0 0 8574 0 10978 0 195179 0 0 0 MATT DEGOOYER SENIOR REGIONAL DIRECTOR 152553 0 4000 0 0 0 11044 0 18192 0 185789 0 0 0 DESIREE WIENAND DIRECTOR, CORPORATE ENGAGE 151742 0 4000 0 0 0 10745 0 15027 0 181514 0 0 0 JOY BUIE VP, RESEARCH 138479 0 20000 0 0 0 6959 0 11766 0 177204 0 0 0 PART I, LINE 7 BONUS LEVELS FOR 2023 WERE ESTABLISHED BASED ON PREDEFINED CATEGORIES ALIGNED WITH EACH EMPLOYEE'S POSITION WITHIN THE ORGANIZATION. ADJUSTMENTS TO THE BASE BONUS AMOUNTS WERE MADE AFTER CONSIDERING INDIVIDUAL FACTORS SUCH AS YEARS OF SERVICE AND OVERALL WORK PERFORMANCE. IN ADDITION, SEVERAL EMPLOYEES RECEIVED INCREASES ABOVE THEIR BASE BONUS DUE TO TAKING ON ADDITIONAL RESPONSIBILITIES THROUGHOUT THE YEAR, PARTICULARLY IN RESPONSE TO STAFFING CHANGES, THE ILLNESS AND PASSING OF THE CEO, AND THE TRANSITIONAL SUPPORT REQUIRED BY THE INTERIM CEO. X 38 25600 FAIR MARKET VALUE X 8 59931 FAIR MARKET VALUE 0 1 1 PART I, LINE 32B: THE LUPUS FOUNDATION OF AMERICA (LFA) IS GRATEFUL TO OUR DONORS FOR DONATING CARS TO SUPPORT THE PROGRAMS OF LFA. LFA HAS ENGAGED A THIRD PARTY, CARS, TO SOLICIT, PROCESS AND SELL THE DONATED VEHICLES FOR LFA. SCHEDULE M, PART I LFA REPORTS NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART III, LINE 4A THE LFA SPEARHEADED THE ANNUAL GLOBAL OBSERVANCE OF WORLD LUPUS DAY ON MAY 10. WE DEVELOPED AND EXECUTED A WORLD-WIDE "MAKE LUPUS VISIBLE" SOCIAL MEDIA CAMPAIGN TO SHARE LUPUS EDUCATION FACTS AND STATISTICS, LEVERAGED THROUGH THE SHARING OF VARIOUS TOOLS, MESSAGES AND IMAGES TO SUCCESSFULLY RAISE AWARENESS OF LUPUS AND ITS IMPACT ON A GLOBAL SCALE. IN PARTNERSHIP WITH THE WORLD LUPUS FEDERATION (WLF), THE LFA DEVELOPED AWARENESS AND ADVOCACY MESSAGES, TOOLS, MATERIALS, LUPUS FACT SHAREABLE IMAGES AND MORE -- ALL PART OF A DIGITAL LUPUS AWARENESS TOOLKIT HOSTED ON WORLDLUPUSDAY.ORG. WE EXECUTED A STRATEGIC COMMUNICATIONS EFFORT TO SHARE AND PROMOTE THE TOOLKIT TO ALL WLF MEMBERS AND SUPPORTERS BOTH LEADING UP TO AND ON WORLD LUPUS DAY AS PART OF A GLOBAL AND COLLABORATIVE SOCIAL MEDIA CAMPAIGN. THROUGH OUR ADVOCACY EFFORTS IN 2024, WE SUPPORTED LUPUS RESEARCH, ACCESS AND EDUCATION BY: HOSTING OVER 320 LUPUS ADVOCATES IN WASHINGTON, DC FOR THE 2024 NATIONAL LUPUS ADVOCACY SUMMIT, THE COUNTRY'S LARGEST LUPUS ADVOCACY EVENT. ADVOCATES MET WITH NEARLY 200 MEMBERS OF CONGRESS AND THOUSANDS MORE JOINED ONLINE, SENDING 1,300 EMAILS TO THEIR ELECTED OFFICIALS URGING THEM TO INCREASE FUNDING FOR LUPUS RESEARCH AND EDUCATION PROGRAMS AND ADVANCE POLICIES THAT IMPROVE THE LIVES OF ALL PEOPLE WITH LUPUS. ADVOCATED FOR $173 MILLION IN FUNDING FOR LUPUS-SPECIFIC RESEARCH AND EDUCATION PROGRAMS FOR FY25, WHICH IF ENACTED WOULD BE THE MOST FUNDING CONGRESS HAS EVER APPROVED FOR LUPUS-SPECIFIC PROGRAMS IN A SINGLE YEAR. KEY PROVISIONS INCLUDED IN FY25 APPROPRIATIONS BILLS: $20 MILLION TO SUPPORT THE NATIONAL LUPUS PATIENT REGISTRY PROGRAM WITHIN THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION, A 100% INCREASE OVER FY24, WHICH IF ENACTED WOULD BRING TOTAL FUNDING FOR THE PROGRAM TO MORE THAN $115 MILLION SINCE ITS CREATION IN 2003 $10 MILLION FOR THE LUPUS RESEARCH PROGRAM AT THE DEPARTMENT OF DEFENSE, WHICH WOULD BRING TOTAL FUNDING FOR THE PROGRAM TO NEARLY $90 MILLION SINCE IT WAS FIRST FUNDED IN FISCAL YEAR 2017 $2 MILLION FOR THE OFFICE OF MINORITY HEALTH AND THE NATIONAL LUPUS TRAINING, OUTREACH, AND CLINICAL TRIAL EDUCATION PROGRAM, A PROGRAM THAT IS WORKING TO INCREASE PARTICIPATION IN LUPUS CLINICAL TRIALS, BREAK DOWN BARRIERS AND ENSURE TRIAL PARTICIPANTS ARE REPRESENTATIVE OF THE LUPUS POPULATION. APPROXIMATELY $50 BILLION $48 BILLION FOR THE NATIONAL INSTITUTES OF HEALTH, THE WORLD'S LARGEST PUBLIC FUNDER OF LUPUS RESEARCH AND WHICH PROVIDED AN ESTIMATED $140 MILLION FOR LUPUS RESEARCH IN 2024 LEADING THE LUPUS RESEARCH ACTION NETWORK (LRAN), A PEER-TO-PEER TRAINING AND EDUCATION PROGRAM CREATED TO INCREASE PATIENT PARTICIPATION IN LUPUS RESEARCH, WITH A SPECIFIC FOCUS ON POPULATIONS THAT ARE UNDERREPRESENTED IN LUPUS RESEARCH AND CLINICAL TRIALS. LRAN IS A KEY COMPONENT OF THE LFA'S IMPACT+ (INCREASING MINORITY PARTICIPATION AND AWARENESS IN CLINICAL TRIALS) GRANT WITH THE U.S DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) OFFICE OF MINORITY HEALTH (OMH). IN 2024, THE LRAN PROGRAM INCLUDED AN IN-PERSON TRAINING AND FOUR ONLINE CONTINUING EDUCATION EVENTS THAT TAUGHT COMMUNITY LEADERS ABOUT CLINICAL TRIALS, THE BARRIERS THAT LIMIT PARTICIPATION AND HOW TO TALK ABOUT TRIALS IN THEIR OWN COMMUNITIES ON A PEER-TO-PEER BASIS. FORM 990, PART III, LINE 4A SECURING ADDITIONAL CONGRESSIONAL SUPPORT FOR THE HELP COPAYS ACT AND SAFE STEP ACT TO IMPROVE ACCESS TO CARE AND REDUCE COSTS FOR PEOPLE WITH LUPUS. THE BILLS WOULD IMPROVE COPAY ASSISTANCE PROGRAMS AND LIMIT STEP THERAPY, RESPECTIVELY AND HELP ENSURE PEOPLE WITH LUPUS HAVE ACCESS TO NEEDED TREATMENTS. THE LUPUS FOUNDATION OF AMERICA'S ADVOCACY HELPED GENERATE 235 COSPONSORS FOR THE SAFE STEP ACT AND 130 FOR THE HELP COPAYS ACT. MOREOVER, IN 2024, FOUR STATES ILLINOIS, NEW MEXICO, NEW YORK, AND VERMONT SIGNED NEW STEP THERAPY PROTECTIONS INTO LAW, BRINGING THE TOTAL TO NEARLY 36 STATES THAT HAVE ENACTED SOME FORM OF STEP THERAPY PROTECTION. LEADING ADVOCACY EFFORTS TO SUPPORT AN EXTENSION OF TELEHEALTH BENEFITS INCLUDING, HELPING TO PASS LEGISLATION IN CONGRESSIONAL COMMITTEES AND AUTHORING AN OPED, TELEHEALTH ACCESS IMPROVES CARE FOR PEOPLE WITH LUPUS, PUBLISHED NATIONWIDE IN REAL CLEAR HEALTH. CONTINUING TO ELEVATE THE PATIENT VOICE IN DRUG DEVELOPMENT, PROVIDING THE LUPUS PATIENT PERSPECTIVE TO CONGRESS AND THE FDA, INCLUDING AS AN ACTIVE LEADER IN PATIENT FOCUSED DRUG DEVELOPMENT (PFDD) WORKS, A GROUP OF TOP PATIENT ORGANIZATIONS WORKING TOGETHER TO ADVANCE PATIENT FOCUSED-DRUG DEVELOPMENT, AND INFORM FDA REGULATORY DECISION-MAKING. THE LUPUS FOUNDATION OF AMERICA ENGAGED THE FDA AS IT DEVELOPED GUIDANCE ON DIVERSITY ACTION PLANS TO IMPROVE ENROLLMENT IN CLINICAL TRIALS FROM UNDERREPRESENTED POPULATIONS AND THE USE OF REAL WORLD DATA AND REAL WORLD EVIDENCE. MOREOVER, THE LFA AND PFDD WORKS LEADERS CALLED ON THE FDA TO MODERNIZE THE AGENCY'S ADVISORY COMMITTEE PROCESS AND THE USE OF ADVISORY COMMITTEES IN NEW DRUG REVIEWS. SERVING AS CO-CHAIR OF THE NIAMS COALITION, SUPPORTING THE NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES, WHICH IS THE LEAD NIH INSTITUTE FOR LUPUS RESEARCH. THE LUPUS FOUNDATION OF AMERICA ALSO CHAIRS THE COALITION'S PATIENT ENGAGEMENT WORK GROUP THAT IS ELEVATING THE PATIENT VOICE AT NIH AND IN NIH SUPPORTED LUPUS RESEARCH. CONTINUING TO LEAD THE MAPRX COALITION, A GROUP OF MORE THAN 60 NATIONAL PATIENT ADVOCACY ORGANIZATIONS DEDICATED TO PROTECTING AND STRENGTHENING THE MEDICARE PART D PRESCRIPTION DRUG BENEFIT FOR THE 53 MILLION AMERICANS ENROLLED IN THE PROGRAM. AS THE LEADER OF THE COALITION, THE LFA ON ENGAGED CONGRESS AND THE CENTERS FOR MEDICARE AND MEDICAID SERVICES THROUGHOUT THE YEAR, INCLUDING HOSTING TWO CONGRESSIONAL BRIEFINGS, SERVING AS A FEATURED SPEAKER AT PATIENT ORGANIZATION EVENTS, AND CONDUCTING OTHER OUTREACH DESIGNED TO EDUCATE LEADERS ON CAPITOL HILL AND THE BROADER PATIENT ADVOCACY COMMUNITY ABOUT MEDICARE POLICY AND THE IMPORTANCE OF PART D TO PEOPLE WITH LUPUS. OF PARTICULAR FOCUS IN 2024 WAS THE IMPLEMENTATION OF KEY PROVISIONS OF THE INFLATION REDUCTION ACT, INCLUDING: A HISTORIC $2,000 OUT-OF-POCKET CAP, THAT FOR THE FIRST TIME EVER, CAPS OUT-OF-POCKET PRESCRIPTION DRUG COSTS FOR PEOPLE WITH LUPUS, WHO PAY $0 AFTER HITTING THE CAP. THE MEDICARE PRESCRIPTION PAYMENT PLAN, A NEW PROGRAM THAT ALLOWS PEOPLE WITH LUPUS TO SPREAD OUT PAYMENTS FOR PRESCRIPTION DRUGS OVER THE YEAR, INTEREST FREE. EXPANDED ELIGIBILITY FOR THE LOW-INCOME SUBSIDY IN PART D TO INCREASE AFFORDABILITY. THE MAPRX COALITION ALSO PRODUCED MULTIPLE EDUCATIONAL RESOURCES, CUSTOMIZED FOR PEOPLE WITH LUPUS, TO HELP MEDICARE BENEFICIARIES NAVIGATE THESE NEW BENEFITS AND THE ANNUAL MEDICARE OPEN ENROLLMENT PERIOD. RESOURCES INCLUDED A GUIDE TO MEDICARE OPEN ENROLLMENT; A GUIDE TO THE MEDICARE PRESCRIPTION PAYMENT PLAN, AN INFOGRAPHIC AND A CALL CENTER SCRIPT TO HELP THOSE WHO WORK WITH PEOPLE LIVING WITH LUPUS AND OTHER MEDICARE BENEFICIARIES. THE MAPRX COALITION PRODUCED TWO CRITICAL PAPERS THAT HELPED TO INFORM IRA IMPLEMENTATION AND ADVANCE THE MEDICARE LEGISLATIVE AND REGULATORY POLICY. THESE INCLUDED: THE IRA'S UNINTENDED CONSEQUENCES FOR MEDICARE PART D IN 2025 AND 2026, AND MINIMIZING AFFORDABILITY CHALLENGES AND BENEFICIARY CONFUSION. AND THE COALITION CONTINUED TO PLAY A LEADING ROLE IN ADVOCATING FOR MEDICARE COVERAGE OF ANTI-OBESITY MEDICATIONS, WHICH ARE IMPORTANT NEW OPTIONS TO TREAT OBESITY, A DISEASE THAT, LIKE LUPUS, DISPROPORTIONATELY IMPACTS WOMEN AND WOMEN OF COLOR. LEADING A NETWORK OF NEARLY 44,000 GRASSROOTS ADVOCATES FROM EVERY STATE AND 435 CONGRESSIONAL DISTRICTS WHO HELPED ADVANCE LUPUS-RELATED PUBLIC POLICY PRIORITIES. FORM 990, PART VI, SECTION A, LINE 7A THE CHAPTERS HAVE THE AUTHORITY TO ELECT THE MEMBERS OF THE NATIONAL COUNCIL REPRESENTATIVES OF THE BOARD OF THE DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B THE CHAPTERS HAVE THE AUTHORITY TO VOTE ON ANY PROPOSED CHANGES BY THE BOARD OF THE DIRECTORS TO THE FOUNDATION'S BYLAWS. FORM 990, PART VI, SECTION B, LINE 11B THE FOUNDATION HIRES AN INDEPENDENT ACCOUNTING FIRM TO PREPARE THE FORM 990. A COPY OF THE FINAL DRAFT OF THE FORM 990 IS REVIEWED AND APPROVED BY THE FINANCE COMMITTEE VIA A TELEPHONE CONFERENCE. ONCE APPROVED BY THE FINANCE COMMITTEE, A COMPLETE COPY OF THE FORM 990 IS DISTRIBUTED TO ALL MEMBERS OF THE BOARD OF DIRECTORS BEFORE FILING THE FORM WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C AT THE FOUNDATION'S BOARD MEETING IN THE FALL, THE CONFLICT OF INTEREST STATEMENT AND QUESTIONNAIRE ARE COMPLETED AND SIGNED BY EACH OFFICER, DIRECTOR, COMMITTEE MEMBER AND KEY EMPLOYEE. ALL CONFLICT OF INTEREST STATEMENTS AND QUESTIONNAIRES ARE REVIEWED BY THE PRESIDENT & CEO AND CHIEF FINANCIAL OFFICER WHO NOTE ANY ACTUAL OR POTENTIAL CONFLICTS. WHEN THERE IS A DOUBT AS TO WHETHER A CONFLICT OF INTEREST EXISTS, THE MATTER SHALL BE RESOLVED BY A VOTE OF THE BOARD OF DIRECTORS (OR ITS COMMITTEE), EXCLUDING THE PERSON CONCERNING WHOSE SITUATION THE DOUBT HAS ARISEN. THERE HAVE BEEN NO CONFLICTS NOTED DURING THE YEAR. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE COMMITTEE OF THE BOARD (EC) CONDUCTS AN ANNUAL PERFORMANCE EVALUATION OF THE PRESIDENT & CEO AND RECOMMENDS SALARY LEVEL CHANGES TO THE BOARD OF DIRECTORS FOR APPROVAL. THE RECOMMENDED CHANGES ARE BASED ON THE MOST CURRENTLY AVAILABLE COMPARABILITY DATA FROM THE MANAGEMENT COMPENSATION SURVEY STUDY PUBLISHED JOINTLY BY THE NATIONAL HEALTH COUNCIL AND THE NATIONAL HUMAN SERVICES ASSEMBLY. ONCE APPROVED, ONE OF THE MEMBERS OF THE EC, GENERALLY THE CHAIRMAN OR THE TREASURER, NOTIFIES THE CHIEF FINANCIAL OFFICER OF THE NEW APPROVED COMPENSATION ARRANGEMENT FOR THE PRESIDENT & CEO. ALL OTHER KEY EMPLOYEES' ANNUAL PERFORMANCE EVALUATIONS ARE CONDUCTED BY THE PRESIDENT & CEO AND THEIR APPROVED ANNUAL SALARY INCREASES ARE DOCUMENTED ON THEIR ANNUAL PERFORMANCE EVALUATION FORM. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION MAKES ITS FINANCIAL STATEMENTS, FEDERAL FORM 990, AND ANNUAL REPORT AVAILABLE TO THE PUBLIC UPON REQUEST AND BY POSTING THEM ON ITS WEBSITE. ALL OTHER GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G ACCOUNTING SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 407,163. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 407,163. RESEARCH SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 183,434. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 183,434. ADVOCACY SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 554,827. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 554,827. ADMINISTRATIVE SUPPORT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 51,692. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 51,692. PATIENT EDUCATION & SUPPORT SERVICE: PROGRAM SERVICE EXPENSES 1,027,195. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,027,195. DEVELOPMENT SUPPORT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 51,921. TOTAL EXPENSES 51,921. MARKETING & COMMUNICATIONS SUPPORT: PROGRAM SERVICE EXPENSES 207,001. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 207,001. FORM 990, PART XI, LINE 9: REFUND OF GRANTS 50,647. LUPUS AMERICA COMMUNITIES 2121 K STREET NW SUITE 200 WASHINGTON DC 20037 900870868 SUPPORTING ORGANIZATION DC 501(C)(3) LINE 12C, III-FI N/A 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0